4006-776-356 出国就医服务电话

免费获得国外相关药品，最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Transepidermal Application of Metilaminolevulinate in Daylight PDT in the Treatment of Photodamaged Skin

Transepidermal Application of Metilaminolevulinate in Daylight PDT in the Treatment of Photodamaged Skin

Study Description
Brief Summary:
Chronic sun exposure enhances the incidence of cutaneous neoplasms (NMSC - non melanoma skin cancer), wrinkles, roughness, telangiectasia and irregular pigmentation of the skin. Nowadays, actinic keratosis (AK) are considered in situ squamous cell carcinoma (SCC), and should be managed that way. Conventional topical Photodynamic therapy (PDT) has proven its efficacy on treatment of AK and cancerization field. PDT's action in global improvement of photodamaged skin, texture, pigmentation and reduction of wrinkles has been well documented in literature. Immunohistochemical and histopathological essays describe the hypothesis of conventional PDT's mechanisms of action in photoaging by dermal remodeling, with enhancement of collagen, statiscally significant. Daylight-Photodynamic Therapy (DL-PDT) is a new modality that keeps the efficacy of topical PDT in treatment of AK and cancerization field, but painless and more practically. Until this moment, there is no report of DL-PDT efficacy on photorejuvenation and actinic keratosis evaluated by clinical, histopathological and immunohistochemical studies. The investigator's aim is to evaluate the alterations induced by isolated DLPDT or DLPDT associated with other techniques of transepidermal drug delivery (microneedles, CO2 laser and microdermabrasion) in the treatment of field cancerization in photodamaged skin with actinic keratosis, through clinical evaluation, histopathological and immunohistochemical studies. It is an interventional, prospective, randomized controlled, parallels-groups, four-arm trial with 1:1 allocation ratio study performed in forty patients attended at the Dermatology Service of Hospital Universitário Antonio Pedro- Universidade Federal Fluminense.

Condition or disease Intervention/treatment Phase
Skin Diseases Procedure: Group I (Standard DL-PDT) Procedure: Group II (DL-PDT with microneedles) Procedure: Group III (DL-PDT with CO2 laser) Procedure: Group IV (DL-PDT with microdermabrasion) Not Applicable

Detailed Description:
This is a randomized controlled, parallels-groups, four-arm trial with 1:1 allocation ratio study on the clinical, histological and immunohistochemical changes induced by Daylight-Photodynamic Therapy (DL-PDT) in 40 patients presenting face-photodamaged skin with actinic keratosis, attended at the Dermatology outpatient clinic of Hospital Antônio Pedro (HUAP) of Universidade Federal Fluminense - UFF, who meet the inclusion criteria and agree to sign the informed consent form (TCLE) for participation in clinical research. There will be four treatment groups with different protocols. These protocols were chosen by hand draw using two boxes containing folded papers. One with the 4 numbers of the groups (1, 2, 3, 4), and another with 4 papers with the names of the protocols. At each draw, one paper from each box was withdrawn, and the combined results from the two boxes defined the treatments of each group. Group I was randomly selected to be DL-PDT alone (standard procedure - group control); Group II was randomly selected to be DL-PDT with TED (microneedles); Group III was randomly selected to be DL-PDT with TED (CO2 laser) and Group IV was was randomly selected to be DL-PDT with TED (microdermabrasion with crystal peeling). Two treatment sessions will be performed with a 4-week interval, regardless of the protocol chosen per group. Patients will be numbered according to the registration for participation in the study. These numbers will be distributed in 4 groups randomly through the computer, using an Apple application called Random (random number generator: seller Mireia Lluch Ortoloa, category utilities, version 1). Each DL-PDT session will consist of: superficial skin curettage all face with a dermatological curette; application of pure chemical sunscreen for 15 minutes; application of methyl-aminolevulinate (Metvix®, GALDERMA), approved by ANVISA under Registration No. 1291600650016, for 30 minutes without occlusion, before exposure to daylight for 2 hours. Regarding the association of techniques, these will be varied according to the group. For clinical evaluation, patient data will be recorded on the evaluation form, and photographs with the same position and lighting patterns will be performed before and after predetermined periods. For histological and immunohistochemical evaluations, skin biopsies will be performed before and after 3 months of the last treatment session.
Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Transepidermic Application of Metilaminolevulinate in Daylight Photodynamic Therapy in the Treatment of Photodamaged Skin
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Transepidermal Application of Metilaminolevulinate in Daylight Photodynamic Therapy in the Treatment of Photodamaged Skin
Actual Study Start Date : February 3, 2017
Actual Primary Completion Date : December 5, 2018
Actual Study Completion Date : December 1, 2020
Arms and Interventions
Arm Intervention/treatment
Active Comparator: Group I (Standard DL-PDT)
  1. Superficial skin curettage all face with a dermatological curette
  2. All exposed skin was covered with pure chemical sunscreen
  3. After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion

In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied.

 Procedure: Group I (Standard DL-PDT)
Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®)
Other Name: Daylight PDT
Experimental: Group II (DL-PDT with microneedles)
  1. Superficial skin curettage all face with a dermatological curette
  2. All exposed skin was covered with pure chemical sunscreen
  3. After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion
  4. A motorized pen with a tip of 17 grouped needles with 0,5mm (Dermapen Beauty®- Korea) was applied without bleeding

In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied.

 Procedure: Group II (DL-PDT with microneedles)
Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microneedles - motorized pen with a tip of 17 grouped needles with 0,5mm (Dermapen Beauty®- Korea) as a techniques of transepidermal drug delivery (TED)
Other Name: Daylight PDT with microneedles
Experimental: Group III (DL-PDT with CO2 laser)
  1. Superficial skin curettage all face with a dermatological curette
  2. All exposed skin was covered with pure chemical sunscreen
  3. After 15 minutes and removing excess sunscreen, Ablative Fractional Laser (AFXL), CO2 laser, roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60 W, 15 mJ/pixel, 125μm/pixel, 2 mm spacing between ablation zones, density <1% (Pixel Alma Lasers ®) was applied, single-pass
  4. A uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion

In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied.

 Procedure: Group III (DL-PDT with CO2 laser)
Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Ablative Fractional Laser (AFXL), CO2 laser, roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60 W, 15 mJ/pixel, 125μm/pixel, 2 mm spacing between ablation zones, density <1% (Pixel Alma Lasers ®) was applied, single-pass
Other Name: Daylight PDT with CO2 laser
Experimental: Group IV (DL-PDT with microdermabrasion)
  1. Superficial skin curettage all face with a dermatological curette
  2. Microdermabrasion with aluminum oxide crystal (Pan Eletronic®) was performed after superficial skin curettage. Three passes on the skin in different directions (vertical, horizontal, and oblique) were applied
  3. All exposed skin was covered with pure chemical sunscreen
  4. After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion

In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied.

 Procedure: Group IV (DL-PDT with microdermabrasion)
Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microdermabrasion - aluminum oxide crystal (Pan Eletronic®) as a techniques of transepidermal drug delivery (TED)
Other Name: Daylight PDT with microdermabrasion
Outcome Measures
Primary Outcome Measures :
  1. Quantitative clinical evaluation of Actinic keratoses [ Time Frame: 6 months ]
    Numbers of Actinic keratoses on the face: count of lesions before treatment and one month/three months/six months after the second session.

  2. Qualitative clinical evaluation of Actinic keratoses [ Time Frame: 6 months ]
    Actinic keratoses will be classified by degrees of thickness (grades 1, 2 and 3), based on the Olsen scale (J Am Acad Dermatol. 1991 May;24(5 Pt 1):738-43), before treatment and one month/three months/six months after the second session.

  3. Qualitative evaluation of global clinical skin change [ Time Frame: 6 months ]
    The overall improvement of photodanificated skin was evaluated using the GAIS scale (Global Aesthetic Improvement Scale) which ranges from: 1 = very much improvement; 2 = marked improvement; 3 = improved; 4 = no change; 5 = worse. Also performed before treatment and one month/three months/six months after the second session.


Secondary Outcome Measures :
  1. Histological evaluation: Routine stain - haematoxylin and eosin [ Time Frame: 1 year ]
    Morphologic study: the aspect of the corneal layer and epidermis, the thickness of the epidermis (distance between granular layer and basal layer), the extension of the keratinocytes atypia, the amount and cytological aspect of melanocytes, the thickness of the subepidermal collagen (distance between membrane basal and onset of solar elastosis in the papillary dermis), distribution of solar elastosis (diffuse or compact distribution), the presence and the type of inflammatory infiltrate, the presence or absence of ectasia in the papillary dermis vessels. These measurements were performed through an ocular lens with a millimeter ruler (Olympus).

  2. Histological evaluation: Special stains (Orcein and Picrosirius) [ Time Frame: 1 year ]

    Orcein (morphologic study): the distribution of solar elastosis and the organization of the elastic fibers (elaunin and oxytalan fibers present in the papillary dermis and dermo-epidermal junction).

    Picrosirius (morphometry of dermis collagen)


  3. Immunohistochemistry: epidermis and dermis [ Time Frame: 1 year ]

    Expression of these substrates:

    Ki 67, P53 (wild type and mutated): percentage and extent (1/3, 2/3 or 3/3) in the epidermis

    Collagen type I and III, MMP 1,3,9, TIMP 1: semiquantitative method: 0, absence of expression; +, weak expression; ++, moderate expression; +++, strong expression.



Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Both gender;
  • Fitzpatrick phototypes I - IV;
  • age between 40 and 75 years;
  • photodamaged skin with at least 1 lesion of actinic keratosis

Exclusion Criteria:

  • Pregnancy and lactation;
  • photosensitivity;
  • smoking;
  • malignant neoplasms;
  • infections;
  • immunosuppression;
  • collagenoses;
  • any systemic disease or emotional/psychological disorder that could contraindicate the procedure.
  • any topical treatment or interventions for at least three months before the study started
Contacts and Locations

Locations
Layout table for location information
Brazil
Hospital Universitário Antonio Pedro - Universidade Federal Fluminense
Niteroi, Rio De Janeiro, Brazil, 24070-035
Sponsors and Collaborators
Universidade Federal Fluminense
Investigators
Layout table for investigator information
Principal Investigator: Maria Claudia Issa Professor
Tracking Information
First Submitted Date  ICMJE April 23, 2019
First Posted Date  ICMJE May 28, 2019
Last Update Posted Date January 19, 2021
Actual Study Start Date  ICMJE February 3, 2017
Actual Primary Completion Date December 5, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 13, 2021)
  • Quantitative clinical evaluation of Actinic keratoses [ Time Frame: 6 months ]
    Numbers of Actinic keratoses on the face: count of lesions before treatment and one month/three months/six months after the second session.
  • Qualitative clinical evaluation of Actinic keratoses [ Time Frame: 6 months ]
    Actinic keratoses will be classified by degrees of thickness (grades 1, 2 and 3), based on the Olsen scale (J Am Acad Dermatol. 1991 May;24(5 Pt 1):738-43), before treatment and one month/three months/six months after the second session.
  • Qualitative evaluation of global clinical skin change [ Time Frame: 6 months ]
    The overall improvement of photodanificated skin was evaluated using the GAIS scale (Global Aesthetic Improvement Scale) which ranges from: 1 = very much improvement; 2 = marked improvement; 3 = improved; 4 = no change; 5 = worse. Also performed before treatment and one month/three months/six months after the second session.
Original Primary Outcome Measures  ICMJE
 (submitted: May 22, 2019)
  • Quantitative clinical evaluation of Actinic keratoses [ Time Frame: 6 months ]
    Numbers of Actinic keratoses on the face: count of lesions before treatment, 30 days after the second session and 3 months after the second session.
  • Qualitative clinical evaluation of Actinic keratoses [ Time Frame: 6 months ]
    Actinic keratoses will be classified by degrees of thickness (grades 1, 2 and 3), based on the Olsen scale (J Am Acad Dermatol. 1991 May;24(5 Pt 1):738-43), before treatment, 30 days after the second session and 3 months after the second session.
  • Qualitative evaluation of global clinical improvement of skin [ Time Frame: 6 months ]
    Improvement of texture (roughness), color (pigmentation) and wrinkles on face skin, 30 days after the second session and 3 months after the second session, using the quartile scale described by Tina Alster and contributors. This scale considers minimal improvement (<25%); moderate (25-50%); (51-75%), and excellent (> 75%).
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 13, 2021)
  • Histological evaluation: Routine stain - haematoxylin and eosin [ Time Frame: 1 year ]
    Morphologic study: the aspect of the corneal layer and epidermis, the thickness of the epidermis (distance between granular layer and basal layer), the extension of the keratinocytes atypia, the amount and cytological aspect of melanocytes, the thickness of the subepidermal collagen (distance between membrane basal and onset of solar elastosis in the papillary dermis), distribution of solar elastosis (diffuse or compact distribution), the presence and the type of inflammatory infiltrate, the presence or absence of ectasia in the papillary dermis vessels. These measurements were performed through an ocular lens with a millimeter ruler (Olympus).
  • Histological evaluation: Special stains (Orcein and Picrosirius) [ Time Frame: 1 year ]
    Orcein (morphologic study): the distribution of solar elastosis and the organization of the elastic fibers (elaunin and oxytalan fibers present in the papillary dermis and dermo-epidermal junction). Picrosirius (morphometry of dermis collagen)
  • Immunohistochemistry: epidermis and dermis [ Time Frame: 1 year ]
    Expression of these substrates: Ki 67, P53 (wild type and mutated): percentage and extent (1/3, 2/3 or 3/3) in the epidermis Collagen type I and III, MMP 1,3,9, TIMP 1: semiquantitative method: 0, absence of expression; +, weak expression; ++, moderate expression; +++, strong expression.
Original Secondary Outcome Measures  ICMJE
 (submitted: May 22, 2019)
  • Histological evaluation: Routine stain - haematoxylin and eosin [ Time Frame: 1 year ]
    Epidermis: thickness of epidermis, grade and extent of keratinocytes atypia (1/3, 2/3 or 3/3), number and morphology of melanocytes. Dermis: thickness of subepidermal collagen (area between the basal membrane and the elastotic material), morphology and distribution of elastotic material, vasodilatation in the papillary dermis, inflammatory infiltrate in the dermis.
  • Histological evaluation: Special stains [ Time Frame: 1 year ]
    Picrosirius: morphology and morphometry of dermis collagen Weigert: morphology and morphometry of the elastotic material and the elastic fibers of dermis Orcein: thickness of subepidermal collagen (area between the basal membrane and the elastotic material) and the elastotic material
  • Immunohistochemistry: epidermis and dermis [ Time Frame: 1 year ]
    Expression of these substrates: Ki 67, P53 (wild type and mutated): percentage and extent (1/3, 2/3 or 3/3) in the epidermis Collagen type I and III, MMP 1,3,9, TIMP 1: semiquantitative method: 0, absence of expression; +, weak expression; ++, moderate expression; +++, strong expression.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Transepidermal Application of Metilaminolevulinate in Daylight PDT in the Treatment of Photodamaged Skin
Official Title  ICMJE Transepidermal Application of Metilaminolevulinate in Daylight Photodynamic Therapy in the Treatment of Photodamaged Skin
Brief Summary Chronic sun exposure enhances the incidence of cutaneous neoplasms (NMSC - non melanoma skin cancer), wrinkles, roughness, telangiectasia and irregular pigmentation of the skin. Nowadays, actinic keratosis (AK) are considered in situ squamous cell carcinoma (SCC), and should be managed that way. Conventional topical Photodynamic therapy (PDT) has proven its efficacy on treatment of AK and cancerization field. PDT's action in global improvement of photodamaged skin, texture, pigmentation and reduction of wrinkles has been well documented in literature. Immunohistochemical and histopathological essays describe the hypothesis of conventional PDT's mechanisms of action in photoaging by dermal remodeling, with enhancement of collagen, statiscally significant. Daylight-Photodynamic Therapy (DL-PDT) is a new modality that keeps the efficacy of topical PDT in treatment of AK and cancerization field, but painless and more practically. Until this moment, there is no report of DL-PDT efficacy on photorejuvenation and actinic keratosis evaluated by clinical, histopathological and immunohistochemical studies. The investigator's aim is to evaluate the alterations induced by isolated DLPDT or DLPDT associated with other techniques of transepidermal drug delivery (microneedles, CO2 laser and microdermabrasion) in the treatment of field cancerization in photodamaged skin with actinic keratosis, through clinical evaluation, histopathological and immunohistochemical studies. It is an interventional, prospective, randomized controlled, parallels-groups, four-arm trial with 1:1 allocation ratio study performed in forty patients attended at the Dermatology Service of Hospital Universitário Antonio Pedro- Universidade Federal Fluminense.
Detailed Description This is a randomized controlled, parallels-groups, four-arm trial with 1:1 allocation ratio study on the clinical, histological and immunohistochemical changes induced by Daylight-Photodynamic Therapy (DL-PDT) in 40 patients presenting face-photodamaged skin with actinic keratosis, attended at the Dermatology outpatient clinic of Hospital Antônio Pedro (HUAP) of Universidade Federal Fluminense - UFF, who meet the inclusion criteria and agree to sign the informed consent form (TCLE) for participation in clinical research. There will be four treatment groups with different protocols. These protocols were chosen by hand draw using two boxes containing folded papers. One with the 4 numbers of the groups (1, 2, 3, 4), and another with 4 papers with the names of the protocols. At each draw, one paper from each box was withdrawn, and the combined results from the two boxes defined the treatments of each group. Group I was randomly selected to be DL-PDT alone (standard procedure - group control); Group II was randomly selected to be DL-PDT with TED (microneedles); Group III was randomly selected to be DL-PDT with TED (CO2 laser) and Group IV was was randomly selected to be DL-PDT with TED (microdermabrasion with crystal peeling). Two treatment sessions will be performed with a 4-week interval, regardless of the protocol chosen per group. Patients will be numbered according to the registration for participation in the study. These numbers will be distributed in 4 groups randomly through the computer, using an Apple application called Random (random number generator: seller Mireia Lluch Ortoloa, category utilities, version 1). Each DL-PDT session will consist of: superficial skin curettage all face with a dermatological curette; application of pure chemical sunscreen for 15 minutes; application of methyl-aminolevulinate (Metvix®, GALDERMA), approved by ANVISA under Registration No. 1291600650016, for 30 minutes without occlusion, before exposure to daylight for 2 hours. Regarding the association of techniques, these will be varied according to the group. For clinical evaluation, patient data will be recorded on the evaluation form, and photographs with the same position and lighting patterns will be performed before and after predetermined periods. For histological and immunohistochemical evaluations, skin biopsies will be performed before and after 3 months of the last treatment session.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Transepidermic Application of Metilaminolevulinate in Daylight Photodynamic Therapy in the Treatment of Photodamaged Skin
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Skin Diseases
Intervention  ICMJE
  • Procedure: Group I (Standard DL-PDT)
    Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®)
    Other Name: Daylight PDT
  • Procedure: Group II (DL-PDT with microneedles)
    Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microneedles - motorized pen with a tip of 17 grouped needles with 0,5mm (Dermapen Beauty®- Korea) as a techniques of transepidermal drug delivery (TED)
    Other Name: Daylight PDT with microneedles
  • Procedure: Group III (DL-PDT with CO2 laser)
    Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Ablative Fractional Laser (AFXL), CO2 laser, roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60 W, 15 mJ/pixel, 125μm/pixel, 2 mm spacing between ablation zones, density <1% (Pixel Alma Lasers ®) was applied, single-pass
    Other Name: Daylight PDT with CO2 laser
  • Procedure: Group IV (DL-PDT with microdermabrasion)
    Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microdermabrasion - aluminum oxide crystal (Pan Eletronic®) as a techniques of transepidermal drug delivery (TED)
    Other Name: Daylight PDT with microdermabrasion
Study Arms  ICMJE
  • Active Comparator: Group I (Standard DL-PDT)
    1. Superficial skin curettage all face with a dermatological curette
    2. All exposed skin was covered with pure chemical sunscreen
    3. After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion

    In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied.

    Intervention: Procedure: Group I (Standard DL-PDT)
  • Experimental: Group II (DL-PDT with microneedles)
    1. Superficial skin curettage all face with a dermatological curette
    2. All exposed skin was covered with pure chemical sunscreen
    3. After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion
    4. A motorized pen with a tip of 17 grouped needles with 0,5mm (Dermapen Beauty®- Korea) was applied without bleeding

    In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied.

    Intervention: Procedure: Group II (DL-PDT with microneedles)
  • Experimental: Group III (DL-PDT with CO2 laser)
    1. Superficial skin curettage all face with a dermatological curette
    2. All exposed skin was covered with pure chemical sunscreen
    3. After 15 minutes and removing excess sunscreen, Ablative Fractional Laser (AFXL), CO2 laser, roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60 W, 15 mJ/pixel, 125μm/pixel, 2 mm spacing between ablation zones, density <1% (Pixel Alma Lasers ®) was applied, single-pass
    4. A uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion

    In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied.

    Intervention: Procedure: Group III (DL-PDT with CO2 laser)
  • Experimental: Group IV (DL-PDT with microdermabrasion)
    1. Superficial skin curettage all face with a dermatological curette
    2. Microdermabrasion with aluminum oxide crystal (Pan Eletronic®) was performed after superficial skin curettage. Three passes on the skin in different directions (vertical, horizontal, and oblique) were applied
    3. All exposed skin was covered with pure chemical sunscreen
    4. After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion

    In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied.

    Intervention: Procedure: Group IV (DL-PDT with microdermabrasion)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 22, 2019) 		40
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE December 1, 2020
Actual Primary Completion Date December 5, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Both gender;
  • Fitzpatrick phototypes I - IV;
  • age between 40 and 75 years;
  • photodamaged skin with at least 1 lesion of actinic keratosis

Exclusion Criteria:

  • Pregnancy and lactation;
  • photosensitivity;
  • smoking;
  • malignant neoplasms;
  • infections;
  • immunosuppression;
  • collagenoses;
  • any systemic disease or emotional/psychological disorder that could contraindicate the procedure.
  • any topical treatment or interventions for at least three months before the study started
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 40 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Brazil
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03963765
Other Study ID Numbers  ICMJE Daylight PDT
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Maria Claudia Almeida Issa, Universidade Federal Fluminense
Study Sponsor  ICMJE Universidade Federal Fluminense
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Maria Claudia Issa Professor
PRS Account Universidade Federal Fluminense
Verification Date January 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

治疗医院

新药特效药

前沿医讯